Cell line · CVCL_1512
Papers32
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 32
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Fast tumor accumulation and payload release of c-Met targeting aptamer-drug conjugate enables robust anti-tumor efficacy. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of the LINE1-derived MET transcript induces apoptosis and oncoprotein knockdown in cancer cells. | Mol Ther Nucleic Acids | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic roles of neutrophil extracellular traps in cancer cell adhesion and activation of Notch 1-mediated epithelial-to-mesenchymal transition in EGFR-driven lung cancer cells. | Front Immunol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. | Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. | Cell Mol Life Sci | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Glycosylated Cathepsin V Serves as a Prognostic Marker in Lung Cancer. | Front Oncol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Lentiviral-Driven Discovery of Cancer Drug Resistance Mutations. | Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| RUVBL1/RUVBL2 ATPase Activity Drives PAQosome Maturation, DNA Replication and Radioresistance in Lung Cancer. | Cell Chem Biol | 2020 | Its Methods give the RRID and name the line | PubMed | |
| From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later. | J Cell Biochem | 2020 | Cellosaurus cites it | PubMed | |
| Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer. | Elife | 2019 | Its Methods give the RRID and name the line | PubMed | |
| Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer. | Oncotarget | 2018 | Cellosaurus cites it | PubMed | |
| Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. | Cell | 2018 | Cellosaurus cites it | PubMed | |
| Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. | Cancer Cell | 2017 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1512/papers